Skip to main content

Blood Glucose Testing a Significant Contributor to Pharmacy Costs in Patients Using Insulin

Web Exclusives - Conference Highlights ADA

San Diego, CA—Blood glucose testing constitutes more than 20% of US pharmacy costs in patients taking insulin, investigators from the IMS Consulting Group, Alexandria, VA, found in a study presented at the 2011 Scientific Sessions of the American Diabetes Association.

“New insulin regimens with simpler, user-friendly dosing options and simpler titration are warranted in order to enable relevant cost-savings,” the researchers stated.

Their study used medical and pharmacy claims data from 102 health plans across the United States. Included in their analysis were 74,936 patients with type 1 or type 2 diabetes with 2 or more prescriptions for insulin of any type, more than 6 months of continuous enrollment in their plan before study inclusion, and more than 12 months of continuous enrollment after study inclusion for outcomes measurement. Of the patients, 43.1% were new to insulin therapy.

Self-measured blood glucose constituted 20.0% ($602 of $2975) of the total annual diabetes-related pharmacy costs. The relative cost of self-measured blood glucose was 15.3% ($399 of $2607) for users of basal insulin only compared with 22.2% ($812 of $3666) for basal-bolus insulin users and 15.1% ($395 of $2617) for users of premixed insulin.

Related Items
Look AHEAD Trial: Intensive Lifestyle Intervention Can Achieve Sustained Weight Loss in Type 2 Diabetes
Alice Goodman
Web Exclusives published on October 26, 2011 in Conference Highlights ADA
Anti-VEGF Antibody Injections Improve Vision in Diabetic Macular Edema
Wayne Kuznar
Web Exclusives published on October 26, 2011 in Conference Highlights ADA
Concern Raised About Ocular Risks of Diabetes Treatments
Alice Goodman
Web Exclusives published on October 26, 2011 in Conference Highlights ADA
Artificial Pancreas Passes Test in Patients with Type 1 Diabetes
Wayne Kuznar
Web Exclusives published on October 26, 2011 in Conference Highlights ADA
Intensive versus Standard Blood Pressure Control of No Benefit in Quality of Life for Patients with Type 2 Diabetes
Alice Goodman
Web Exclusives published on October 26, 2011 in Conference Highlights ADA
Last modified: August 30, 2021